Collectively, I13 possesses an interesting property that makes it a promising compound for further investigation in order to potentially overcome the current limitations of CML therapy caused by the BCR-ABL-T315I mutation. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.